Cargando…
FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer
BACKGROUND: Bladder cancer is a common disease worldwide with most patients presenting with the non-muscle-invasive form (NMIBC) at initial diagnosis. Postoperational intravesical instillation of BCG is carried out for patients with high-risk disease to reduce tumor recurrence and progression to mus...
Autores principales: | Zhang, Yang, Huo, Fan, Cao, Qiang, Jia, Ru, Huang, Qiju, Wang, Zhu A, Theodorescu, Dan, Lv, Qiang, Li, Pengchao, Yan, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8971803/ https://www.ncbi.nlm.nih.gov/pubmed/35361729 http://dx.doi.org/10.1136/jitc-2021-003939 |
Ejemplares similares
-
Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin
por: Ylösmäki, Erkko, et al.
Publicado: (2021) -
Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021) -
Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
por: Zhang, Wei, et al.
Publicado: (2020) -
Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022) -
Catch-bond mechanism of the bacterial adhesin FimH
por: Sauer, Maximilian M., et al.
Publicado: (2016)